Pharming Group N.V.
PHAR · NASDAQ
Bulios Fair Price
$6.19
41.3% downside
Current Price
$10.55
According to Bulios Fair Price, PHAR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Pharming Group N.V. is a Dutch biotechnology company that specializes in the development and commercialization of innovative drugs targeting genetically determined diseases and immune disorders. The company is particularly known for its work in producing therapeutic proteins, including medications for the treatment of rare diseases. Pharming is recognized for its research in genetic therapy and recombinant biotechnology, especially concerning the production of medicinal substances aimed at improving the quality of life for patients with severe conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Fabrice Chouraqui
Employees
407
Headquarters
Leiden
Upcoming events
Earnings
Upcoming earnings report